TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00003926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Patients receive oral busulfan every 6 hours on days -8 to -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: All patients receive filgrastim (G-CSF) IV for 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: All patients receive filgrastim (G-CSF) IV for 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: melphalan intravenous (IV) over 30 minutes on days -5 and -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: melphalan intravenous (IV) over 30 minutes on days -5 and -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: thiotepa intravenous (IV) over 2 hours on days -3 and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: thiotepa intravenous (IV) over 2 hours on days -3 and -2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation (PBSC)
Description: PBSC are reinfused on day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation (PBSC)
Description: PBSC are reinfused on day 0
Study: NCT02727790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulator
Study: NCT02429232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 30mg/tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: Linagliptin 5mg/tablet once daily
Study: NCT04244708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus temozolomide
Description: undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy plus placebo
Description: undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus placebo
Study: NCT01456299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 1
Description: Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group, which received an infusion of normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 2
Description: Remifentanil 2: The R2group, which received a target effect-site remifentanil concentration of 2 ng/ml.
Study: NCT01683617

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional coping skills and relaxation training
Study: NCT01633827

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Subjects will receive a sugar pill (in combination with room air) during their placebo arm studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedative
Description: Subjects will receive eszopiclone (in combination with medical oxygen) during their treatment arm studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room air
Description: Subjects will receive room air (in combination with a sugar pill) during their placebo arm studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Subjects will receive medical grade oxygen (in combination with eszopiclone) during their treatment arm studies
Study: NCT01999309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
Study: NCT02354378

Intervention type: DRUG
Intervention: Dexmedetomidine

Intervention type: OTHER
Intervention: Memory Test

Intervention type: OTHER
Intervention: Memory Test
Study: NCT02266836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyndMove
Description: During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
Study: NCT00957983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BGC20-1531
Description: oral administration followed by Prostaglandin E2 infusion
Study: NCT01454154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: Administered as specified in the Treatment Arm.
Study: NCT00957983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BGC20-1531
Description: oral administration followed by Prostaglandin E2 infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BGC20-1531
Description: oral administration followed by Prostaglandin E2 infusion
Study: NCT01725945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension dietary pattern
Description: The intervention will employ a series of small group and individual sessions, followed by periodic telephone contacts, to help participants make appropriate dietary changes and develop the skills to maintain these changes over the long term. The initial 3 months of intensive intervention will involve 8 group and 3 individual sessions for 45-60 minutes each. During the next 3 months, participants will receive counseling phone calls once per month for 20-30 minutes each call. Group session sizes may range from 8-15 participants.
Study: NCT02159105

Intervention type: DEVICE
Intervention: FAST scan and non-invasive hemoglobin measurement
Description: A FAST scan, or abdominal ultrasound will be performed within one hour of cesarean delivery to establish normal levels of postoperative intraabdominal fluid.~Women will also have their hemoglobin measured via a non-invasive method, the Masimo Pronto 7, at 3 time points: immediately prior to surgery (within 2 hours), immediately after surgery (within 1 hour), and the morning following surgery (within 24 hours).
Study: NCT03150498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTD-001
Description: BTD-001 in fed vs fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTD-001
Description: BTD-001 in fed vs fasted state
Study: NCT04485988

Intervention type: DRUG
Intervention: Beta blocker
Description: Duration of medication
Study: NCT00720798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: For participants weighing \> 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disease-modifying anti-rheumatic drugs
Description: Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs
Description: Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Description: Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
Study: NCT01537484

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage Therapy
Description: Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Massage Therapy
Description: Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
Study: NCT01803152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells Vaccine
Description: Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic Cells Vaccine
Description: Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lysate of Tumor
Description: Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lysate of Tumor
Description: Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Post-surgery, Leukapheresis and clearance of subject. Gemcitabine 1000 mg/m2 IV will be administered once weekly for 3 weeks per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Leukapheresis
Description: Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
Study: NCT01809613

Intervention type: PROCEDURE
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: During the deep brain stimulation (DBS) surgery of the subthalamic nucleus within the thalamocortical basal ganglion, an additional lead extendor will be connected to the DBS electrode to allow externalization of the lead. Following confirmation of electrode location with MRI, a series of fMRI scans will be run. Total scanning time will be limited to 35 minutes.
Study: NCT00757913

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 enriched nutrition
Study: NCT01454154

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the Treatment Arm.
Study: NCT03160612

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Transfer Training
Description: Transfer training interventions will take approximately 1 hour to complete and consist of an interactive web based module that participants interact with which includes text, pictures, videos and time to practice new skills. Additionally, participants will receive an educational handout summarizing the online module.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Transfer Training
Description: Transfer training interventions will take approximately 1 hour to complete and consist of an interactive web based module that participants interact with which includes text, pictures, videos and time to practice new skills. Additionally, participants will receive an educational handout summarizing the online module.
Study: NCT04282148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABT NG DES 48 EECSS
Description: Each participant will receive ABT NG DES 48 EECSS with appropriate diameter
Study: NCT03269721

Intervention type: PROCEDURE
Intervention: Systemic Vascular Measures
Description: Carotid artery ultrasound, pulse wave velocity, brachial artery endothelium-dependent flow mediated dilation and endothelium-independent dilation will be measured.
Study: NCT01224184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Women's CoOp
Description: Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Staying Healthy and Eating Well
Description: Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
Study: NCT04438083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX130
Description: CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
Study: NCT03269721

Intervention type: BIOLOGICAL
Intervention: Blood Biomarkers
Description: High sensitivity C-reactive protein (hs-CRP), and fibrinogen will be used as indicators of systemic inflammation, complete blood count with differential (CBC with diff) will be obtained to rule out acute infection as a cause of inflammation.

Intervention type: BIOLOGICAL
Intervention: Blood Biomarkers
Description: High sensitivity C-reactive protein (hs-CRP), and fibrinogen will be used as indicators of systemic inflammation, complete blood count with differential (CBC with diff) will be obtained to rule out acute infection as a cause of inflammation.

Intervention type: BIOLOGICAL
Intervention: Blood Biomarkers
Description: High sensitivity C-reactive protein (hs-CRP), and fibrinogen will be used as indicators of systemic inflammation, complete blood count with differential (CBC with diff) will be obtained to rule out acute infection as a cause of inflammation.
Study: NCT03551275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-132
Description: Dose Escalation Study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-132
Description: Dose Escalation Study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-132
Description: Dose Escalation Study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-132
Description: Dose Escalation Study
Study: NCT02524041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood specimen
Description: blood specimen
Study: NCT04113954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Injection
Description: Injection of 0.375% mepivacaine in nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Injection
Description: Injection of 0.375% mepivacaine in nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Injection
Description: Injection of 0.375% mepivacaine in nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Injection
Description: Injection of 0.375% mepivacaine in nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Injection
Description: Injection of 1.5% mepivacaine in nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Injection
Description: Injection of 1.5% mepivacaine in nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Injection
Description: Injection of 1.5% mepivacaine in nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Injection
Description: Injection of 1.5% mepivacaine in nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Injection
Description: Injection of 1.5% mepivacaine in nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Injection
Description: Injection of 1.5% mepivacaine in nerve block
Study: NCT02605226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation therapy
Description: Cryoablation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: External beam radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luteinizing-hormone releasing-hormone (LHRH) agonist
Description: luteinizing-hormone releasing-hormone (LHRH) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luteinizing-hormone releasing-hormone (LHRH) agonist
Description: luteinizing-hormone releasing-hormone (LHRH) agonist
Study: NCT05598242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic membrane extract eye drops (AMEED)
Description: Following a 2-week wash out period, patients were allocated randomly to receive AMEED, administered as 1 drop in each eye 6 times daily, respectively, for 30 days.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane extract eye drops (AMEED)
Description: Following a 2-week wash out period, patients were allocated randomly to receive AMEED, administered as 1 drop in each eye 6 times daily, respectively, for 30 days.
Study: NCT00597948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Curriculum
Description: Three consecutive days of six hours of training comprised of instruction and participant interaction.
Study: NCT00943306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Description: 5-60 mg po every day
Study: NCT00973661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic tool set for counseling overweight patients
Description: Physicians randomized to the electronic tools arm will receive access to a tool set to aid with counseling of overweight patients. This tool set includes the following components: automatic calculation of BMI, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. Physicians randomized to the usual care arm will not receive access to these tools, and will continue to provide their usual care for overweight patients.
Study: NCT03177122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: Patients belonging to this group will receive 1 gram of Myo-Inositol, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) starting 6 weeks prior to stimulation and extending until final oocyte maturation, combined with 400 µg of folic acid supplemented daily.
Study: NCT03269721

Intervention type: BEHAVIORAL
Intervention: Symptom Questionnaire Measures
Description: M.I.N.I Screen 7.0.0, Beck Depression Inventory-II (DBI-II), State Trait Anxiety Inventory (STAI), COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), MMRC Dyspnea Scale (MMRC), Berlin Questionnaire
Study: NCT03455322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine versus midodrine & octreotide
Description: either intravenous infusion (IVi) norepinephrine in a dose of 0.05-0.3ug/Kg/min. to keep mean arterial pressure ≥ 80-100mmHg \& continued either until HRS reversal or for maximum 10 days or oral midodrine 5mg three times/day \& can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous \& if needed increased to 200ug/6h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine versus midodrine & octreotide
Description: either intravenous infusion (IVi) norepinephrine in a dose of 0.05-0.3ug/Kg/min. to keep mean arterial pressure ≥ 80-100mmHg \& continued either until HRS reversal or for maximum 10 days or oral midodrine 5mg three times/day \& can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous \& if needed increased to 200ug/6h.
Study: NCT01970605

Intervention type: PROCEDURE
Intervention: Surgical reconstruction
Description: In contrast to silver acetate impregnated vascular graft, Silver Graft can be immersed in an antibiotic containing solution prior to implantation. This practice should always be followed according to each participant's hospital guidelines and experience. The long term efficacy of the metallic silver coating will not be reduced.~Common practice antibiotic co-medication before, during and after surgery needs to be documented but is at the discretion of each participating institution.~Due to the registry character of this assessment, i.e. routine use of the investigational product, local antibiotics, e.g. dipping of the vascular graft into a rifampin solution is permissible.
Study: NCT04309084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK-001
Description: CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
Study: NCT01957501

Intervention type: OTHER
Intervention: MDDScoreTM
Description: The child will receive a single blood draw (about 10 mL).

Intervention type: OTHER
Intervention: MDDScoreTM
Description: The child will receive a single blood draw (about 10 mL).

Intervention type: OTHER
Intervention: MDDScoreTM
Description: The child will receive a single blood draw (about 10 mL).